Gastric cancer is one of the most common malignant
tumors and patients show a short survival, those combined with bone marrow invasion have a median survival of only 37 days. Here we reported the treatment of a 47-year-old male with advanced
gastric cancer and complicated with bone marrow invasion and extensive
metastases, who did not tolerate
chemotherapy, under monotherapy with
savolitinib, a
MET receptor tyrosine kinase inhibitor. Before treatment, the patient was in severe
pain and presented with
thrombocytopenia and hemorrhagic
anemia.
Savolitinib was given based on amplification and rearrangement of the MET gene in his
tumor. After
savolitinib treatment, the patient's condition promptly improved, efficacy evaluation indicated partial remission, and the patient was alive and remained progression-free at 15 weeks at the time of reporting. No obvious adverse reactions occurred. Besides, another case of a female
gastric cancer patient with MET amplification who received
savolitinib monotherapy as a third-line treatment that remained progression-free at 12 weeks was also reported. This report provides a new reference for understanding MET abnormalities in
gastric cancer and offers a possibility for future application of MET
tyrosine kinase inhibitors in the
therapy of
gastric cancer with MET abnormalities. Also, it suggests that sequencing of MET can be considered a routine target in advanced
gastric cancer patients.